Latest News

News / 12 Jul 2021

Summit Therapeutics Presents Breakthrough Research Data from Ph II Studies, including Evidence Validating Microbiome Preservation, Potential Benefit for the Control of Antimicrobial Resistance, and a Novel Mechanism of Action, for its Investigational Drug Ridinilazole

News / 01 Jul 2021

Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster

News / 08 Jun 2021

Summit Therapeutics set to join Russell 3000® Index

We are building a very differentiated company that focuses on bringing innovation to the treatment of high unmet medical needs by focusing on the cause of the condition and sparing the rest of the incredible ecosystem that is the human body. Precision-targeting agents will be the new standards of care because they benefit patients and healthcare providers by minimizing trauma while curing the disease, which, in turn, creates value for society and payers alike.

Bob Duggan
Chairman & Chief Executive Officer

Partners

BARDA

Summit is proud to partner with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), as initially announced on September 11, 2017, on its two Phase III pivotal trials, Ri-CoDIFy 1 & 2, investigating ridinilazole for the treatment and reduction of recurrence of C. difficile infection.

CARB-X

Summit is proud to partner with CARB-X, as announced on May 18, 2021, to progress the development of its precision antibiotic candidate, SMT-738, through its IND-enabling and Phase Ia clinical trials for the treatment of highly-resistant CRE bacterial infections.